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Abstract 
Aim: The study aimed to investigate whether textural features of rectal cancer on magnetic 
resonance imaging (MRI) can predict long term survival in patients treated with long-course 
chemoradiotherapy. 
Method: Textural analysis (TA) using a filtration-histogram technique of T2-weighted pre- 
and six-week post chemoradiotherapy MRI was undertaken using TexRAD, a proprietary 
software algorithm. Regions of interest enclosing the largest cross-sectional area of the 
tumour were manually delineated on the axial images and filtration-step extracted features at 
different anatomical scales (fine, medium, and coarse) followed by quantification of statistical 
features (mean intensity, standard-deviation, entropy, skewness, kurtosis and mean of 
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positive pixels [MPP]) using histogram analysis. Cox multiple regression analysis determined 
which univariate features including textural, radiological and histological, independently 
predicted overall survival (OS), disease free survival (DFS) and recurrence-free survival 
(RFS).  
Results: MPP (fine-texture, HR: 6.9, 95% CI [2.43–19.55], p= <0.001), mean (medium-
texture, HR: 5.6 [1.4-21.7], p=0.007) and extramural venous invasion (EMVI) on MRI  (HR: 
2.96, [1.04–8.37], p=0.041) independently predicted OS while mean (medium texture, HR: 
4.53, [1.58–12.94], p=0.003), MPP (fine texture, HR: 3.36 [1.36–8.31], p=0.008) and 
threatened circumferential resection margin (CRM) on MRI (HR: 3.1 [1.01–9.46], p=0.046) 
predicted DFS. For OS; EMVI on MRI (HR: 4.23 [1.41-12.69], p=0.01) and for DFS; kurtosis 
(medium-texture, HR: 3.97 [1.44–10.94], p=0.007) and CRM involvement on MRI (HR: 3.36 
[1.21–9.32], p=0.02) were the independent post-treatment factors. Only TA independently 
predicted RFS on pre- or post-treatment analyses. 
Conclusion: MR based TA of rectal cancers can predict outcome before undergoing surgery 
and could potentially select patients for individualized therapy. 
 
Key words 
Textural analysis, imaging biomarker, rectal cancer, neoadjuvant chemoradiotherapy, MRI 
What does this paper add to the literature? 
This study shows that MRI-based textural analysis of rectal cancer can act as a prognostic 
imaging biomarker and is an independent predictor of survival in patients with locally 
advanced rectal cancer. This finding could contribute to disease risk stratification and allow 
therapy to be individualised. 
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Introduction 
Currently the standard management of locally advanced rectal cancer is neoadjuvant 
chemoradiotherapy followed by total mesorectal excision (TME).1 This strategy combined 
with high resolution magnetic resonance imaging (MRI) has shown considerable 
improvement in locoregional control. This is not, however, the case for systemic control and 
these strategies may not necessarily improve survival.2 Furthermore, restaging of irradiated 
rectal cancer is difficult owing to the difficulty MRI has in differentiating fibrosis from viable 
tumour.3 In addition, a proportion of such patients will have achieved complete clinical 
response and could benefit from either a “wait and watch” approach or less invasive local 
excision.4 There is, however, a poor correlation of a clinical complete response with a true 
pathologic complete response.5 This has resulted in the recent interest on the quantification 
of imaging biomarkers linked to underlying intra-tumour heterogeneity6 associated with the 
adverse outcomes of treatment failure and drug resistance. 7,8 Heterogeneity can be 
quantified non-invasively by imaging using textural-analysis (TA). TA assesses the 
distribution of pixel grey-level intensity and the coarseness and regularity of digital images.9 
In the last decade, TA has been employed in oncological studies of lung10, brain11, renal12 
and breast13 cancer as a diagnostic, prognostic and treatment response imaging biomarker. 
To date there has been no study to assess the potential of MRI-based TA (MRTA) in 
predicting survival in rectal cancer but a few studies have explored the potential of 
computerised tomography [CT]-based TA as a prognostic tool to assess survival in patients 
with  colorectal cancer.14,15 The main object of the present study was to investigate whether 
MRTA in rectal cancer can predict long term survival. 
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Method 
Patient Selection 
Ethical approval was obtained from the institutional ethics committee.  A retrospective cohort 
was included of consecutive patients with stage II and III MRI-defined poor risk, histologically 
confirmed primary non-metastatic rectal adenocarcinoma originating within 15cm of the anal 
verge and treated with long course chemoradiotherapy with curative intent from 01/2006 to 
06/2011. MRI-defined features of poor risk were a  T3 tumour with > 5 mm infiltration into the 
perirectal fat, T4 tumours, N1 or N2- tumours and tumours with a threatened or involved 
circumferential resection margin (CRM).16 Details of long course chemoradiotherapy 
protocol, technical and operative specifications are described elsewhere.17 
MR protocols and acquisition parameters 
MRI was performed with the same GE Sigma Genesis 1.5-T (software version 9.0) whole-
body system using a torso coil (phased array) and a standard imaging protocol without 
intravenous contrast enhancement (Appendix-1). Restaging CT of the chest, abdomen and a 
pelvic MRI scan were performed approximately six weeks after the completion of 
chemoradiotherapy (CRT). Following MDT review, a date for surgery was arranged for 
patients with no response or with evidence of substantial downstaging,. Those with a partial 
response were further followed and a second MRI was performed four weeks after the first 
staging MRI, to optimise the timing of surgery at the point of maximal response.18  
Image Interpretation 
T-staging of tumour at pre-treatment (mrT) and post treatment (ymrT) were standardized 
(Appendix-2) and based on the interpretation of local extent of persistent tumour signal 
intensity relative to the layers of bowel wall on T2 weighted images.19,20 Nodal stage at 
baseline (mrN) and after CRT  (ymrN) was based on the interpretation of lymph node border 
characteristics and signal intensity. A node was regarded as positive if either an irregular 
border or mixed signal intensity was demonstrated.21 Pre- and post-treatment circumferential 
resection margin (CRM) involvement (mrCRM and ymrCRM) was predicted to be clear if the 
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distance of the tumour from the mesorectal fascia was greater than or equal to 1mm. Pre- 
and post-treatment extramural venous invasion (mrEMVI and ymrEMVI) was visualised as 
an intermediate signal intensity apparent within vessels with accompanying nodular 
expansion of the vessel or an irregular vessel contour.22 The tumour response to CRT was 
defined by MRI both on the pathological tumour regression grade (TRG) originally described 
by Dworak (Appendix-3)19,23 and a modified Response Evaluation Criteria in Solid Tumours 
(RECIST) based on the maximum tumour length measured in the sagittal plane.24,25 For 
RECIST, a partial response to treatment was defined as at least a 30% decrease in tumour 
length in relation to the baseline tumour length. Progression of disease was defined as at 
least a 20% increase in tumour length and stable disease was defined as neither sufficient 
shrinkage to qualify for a partial response nor a sufficient increase to qualify for progression 
of disease. MRI scans were reviewed by two independent radiologists (AA, UP) blinded to 
the clinical outcome. Any discrepancy in reporting was resolved by discussion and 
consensus when required. 
 
MR Textural Analysis (MRTA) 
T2-weighted pre-treatment and a 6-week post CRT MRI were used for MRTA. Regions of 
interest (ROIs) enclosing the largest cross-sectional area of tumour area were manually 
delineated on the axial images under the supervision of a gastrointestinal radiologist (AA) 
with seven years’ experience. The ROIs underwent textural analysis under the supervision of 
an imaging scientist (BG) with nine years experience in texture analysis using proprietary 
commercially available TexRAD research software (version 3.3, TexRAD Ltd 
www.texrad.com, part of Feedback Plc, Cambridge, UK)26. MRTA comprised an image 
filtration-histogram approach where the filtration step employed a  Laplacian of Gaussian 
band-pass spatial scale filter (SSF) to highlight features ranging from SSF=2mm (fine) to 
SSF=6mm (coarse) in radius with SSF=3mm-5mm in radius corresponding to medium-
texture scales (Figure 1). This scale can be considered as the width at which structures in 
the image will be highlighted and enhanced, while structures less than this width will become 
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blurred.8 Histogram analysis comprised quantifying first-order statistics of mean grey level 
intensity, standard-deviation, entropy, mean of positive pixels (MPP), kurtosis and skewness 
of the rectal ROI. A recent paper27describes the above parameters in detail and what these 
parameters mean in terms of image features. These parameters have further been shown to 
be associated with underlying histological features reflecting tumour heterogeneity (solid 
cancerous tissue, necrosis, angiogenesis, hypoxia and fibrosis28,29), predicting the response 
to neoadjuvant chemoradiotherapy30and survival8, 26as a potential imaging biomarker. 
Histopathological examination of the resected specimen 
The histopathological information was retrieved from the institutional pathology database. All 
the reports contained a standard data-set of histopathology results such as post-treatment 
pathological T and N stage (ypT and ypN) and included the information regarding the 
circumferential resection margin (ypCRM) involvement according to rectal carcinoma 
guidelines of Royal College of Pathologists.31  
Survival  
Overall survival (OS), disease free survival (DFS) and relapse free survival (RFS) were 
measured. All observations were censored at the date of the last follow-up or at the time lost 
to follow up. The duration of follow up was calculated from the date of diagnosis to death, 
last contact or date of conclusion of the study (21.03.2014) whichever came first. Overall 
survival was defined as the “time from the date of diagnosis to death from any cause”.  
Disease free survival was defined as the “time from the date of diagnosis to any event, 
irrespective of the cause”. Relapse free survival was defined as the “time from the date of 
diagnosis to any event except for second primary same  or other cancers that were 
ignored”32. Local recurrence was defined as evidence of recurrent tumour mass within the 
pelvis or in the perineum after a surgical resection33. 
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Data analysis 
Clinical, MR and histopathological variables were categorized in a binary fashion to enable 
comparison by multivariate analysis. Clinical variables included age, gender, adjuvant 
chemotherapy and major post-operative complications based on the Clavien-Dindo 
classification for surgical complications.34 Tumours were categorized into “favourable” and 
“unfavourable” responders to enable binary comparison by multivariate analysis. Based on 
the known histopathological outcome, “favourable” mrT and ymrT stages were defined as 
stages T0, T1, T2 and T3a and “unfavourable” were defined as mrT and ymrT stages- T3b, 
T3c, T3d or T4. Stage T3a and T2 tumours have a similar outcome and therefore were both 
classified as “favourable”. “Favourable” mrN, ymrN and ypN were defined as N0, while node 
positivity was unfavourable. “Favourable” mrEMVI, ymrEMVI was defined as having no 
EMVI, while the presence of EMVI was “unfavourable”. A “favourable” MRI tumour 
regression grade (mrTRG) was defined as grades 1, 2 & 3 that included tumours with a 
fibrotic stroma of 50% or more while “unfavourable” was defined as grades 4 and 5 that 
included tumours in which cancer predominated with minimal or no fibrosis. Similarly a 
“favourable” histopathological TRG was defined by Dworak stages 2, 3 and 4 while an 
“unfavourable” TRG was defined as grades 0 and 1. For analysis of the length of the tumour, 
a partial response was categorised as “favourable”, while stable or progression of disease 
was “unfavourable”. 
 
Statistical Analysis 
Continuous variables were expressed as means and SDs and categorical variables were 
expressed as percentages and 95% confidence intervals. Univariate Kaplan-Meier survival 
analysis was employed to identify which texture parameter predicted survival, which further 
required the identification of the best "optimal" cut-off at which the good and poor survival 
patient groups were optimally separated (lowest p value from the Log-rank test which 
assessed the difference between the Kaplan-Meier curves) for each parameter. A p-value of 
less than 0.05 was considered to be significant. Due to small numbers, significant textural 
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parameters yielding less than 10 patients per group for comparison were not reported and 
hence were censored. Multivariate Cox regression analysis (Forward-Wald) was used to 
determine which of the significant univariate variables were independent predictors of 
outcome. Analysis was performed separately for pre and post-treatment variables. The 
hazard ratio (HR) was determined for the variables where HR >1 indicated increased risk of 
an event associated with the variable and HR <1 indicated a reduced risk related to survival. 
Statistical analysis was performed using R software (version 2.14.2; R Foundation for 
Statistical Computing, Vienna, Austria) and SPSS (version 20). 
 
Results 
The study population consisted of 56 patients (34 male, 22 female) with meanage of 64 ± 
8.8. Complete pathological response (T0N0) was observed in 21% of patients (n-12). Overall 
recurrence was observed in 23% of patients (n-13). The rate of distant and local recurrence 
was 20% and 5% (Table 1). Pre- and post-treatment MR TNM staging is shown in Table 2. 
The average follow up for the entire cohort was 47.2 ± 18.2 months. Thirty six (36/50, 64%) 
patients were alive and censored when the data were analysed at an average follow up of  
56±11.6 months . The mean overall survival was 65.7% (95% CI, 57.9 -73.8 and the five 
year cumulative survival time was 64%. The mean DFS and five year cumulative DFS were 
similar i.e. 60 months (95% CI, 51.2-69.2). The mean RFS was 70.8 (95% CI, 62.4 – 79.2) 
months. All relapses had occurred by 21 months at which time the cumulative survival time 
was 75%.  
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Survival  
a. Overall Survival 
Pre-treatment variables 
MRTA was a significant marker of OS on univariate analysis with MPP (fine texture scale) 
being the best (p=0.008, Table 3). Positive mrEMVI status (p=0.017, Table 4) and 
threatened mrCRM (p=0.036, Table 4) were also significant MR factors. The clinical variable 
of a major complication also predicted a worse OS (p=0.002) but as this was a post-
operative rather than a pre-treatment or post-treatment factor, it was not included in the 
multivariate analysis. On multivariate analysis, MPP on fine texture-scale (HR: 6.9, 95% CI: 
2.4 – 19.5, p<0.001), MPP on medium texture-scale (HR: 5.7, 95% CI: 1.6 – 20.2, p=0.007) 
and mrEMVI positive status (HR: 2.9, 95% CI: 1. – 8.3, p=0.041) were the only independent 
predictors of OS (Table 5, Figures 2-a, 2-b and 2-c). 
 
Post-treatment variables 
Texture feature, skewness at fine texture-scale, was the only univariate marker of OS on 
post-treatment MRTA (p=0.034, Table 3). Positive ymrEMVI status (p=0.002, Table 4), 
threatened ymrCRM (p=0.027, Table 4) and poorer ymrTRG (p=0.002, Table 4) predicted a 
worse OS. Among the histological variables, only ypCRM involvement (p=0.007, Table 4) 
predicted the OS. On multivariate analysis, positive ymrEMVI status (Table 5, Figure 2-d) 
was the only independent predictor of OS (HR: 4.2, 95% CI: 1.4- 12.6, p=0.01) 
 
b. Disease free survival 
Pre-treatment variables 
A threatened mrCRM (p=0.006, Table 4) and MRTA (best feature-mean at medium texture, 
p=0.007, Table 3) were significant markers for DFS on univariate analysis. On multivariate 
analysis, MPP at fine texture-scale (HR: 3.3 95% CI: 1.3 – 8.3, p=0.008), mean MPP at 
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medium texture-scale (HR: 4.5, 95% CI: 1.5 – 12.9, p=0.003), and threatened mrCRM (HR: 
3.1, 95% CI: 1. – 9.4 p=0.046) were the only independent predictors of DFS (Table 5, 
Figures 3a, 3b and 3c). 
 
Post-treatment variables 
Post-treatment MRTA (best was kurtosis at medium texture-scale, p=0.009, Table 3), 
positive mrEMVI status (p=0.017, Table 4), threatened mrCRM (p=0.019, Table 4), mrTRG 
(p=0.02, Table 4) and ypCRM (p=0.035, Table 4) were significant markers of DFS on 
univariate analysis. On multivariate analysis, kurtosis at medium texture-scale (HR: 3.9, 95% 
CI: 1.4 – 10.9, p=0.007) and ymrCRM involvement (HR: 3.3 95% CI: 1.2 – 9.3, p=0.02) were 
the only independent predictors of DFS (Table 5, Figures 3d and 3e). 
 
c. Relapse free survival 
Pre-treatment variables 
A threatened mrCRM (p=0.016, Table 4) and MRTA were significant markers for RFS on 
univariate analysis (Table 3).The best textural features were standard deviation and entropy 
at coarse-textures (p=0.011) and MPP at fine and medium-textures (p=0.011).Using 
multivariate analysis, texture parameters of MPP at fine texture-scale (HR: 8.9, 95% CI: 2.3 
–33.1, p= 0.001) and kurtosis at medium texture-scale (HR: 7.7 95% CI: 2. - 29., p=0.002) 
were the only independent predictors (Table 5, Figures 4a and 4b). 
 
Post-treatment variables 
Post-treatment MRTA (best was entropy at coarse-texture, p=0.002, Table 3), ymrN-stage 
(p=0.024, Table 4), ypCRM involvement (p=0.009, Table 4) and pCR (p=0.034, Table 4) 
were significant markers of survival on univariate analysis. On multivariate analysis, texture 
parameters, entropy at coarse texture-scale (HR: 8.6, 95% CI: 1.8 – 39.8, p=0.005) and 
kurtosis without filtration (HR: 4.2, 95% CI: 1.4- 13., p=0.01) were the only independent 
predictors of RFS (Table 5, Figures 4c and 4d). 
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Discussion 
This is the first study to assess the prognostic significance of texture features in addition to 
morphological MRI and histopathological parameters of rectal cancer undergoing CRT. On 
pre-treatment MRTA a lower MPP at fine-texture was an independent predictor for all three 
forms of survival. A lower mean MPP at medium-texture was an independent predictor of OS 
and DFS and kurtosis at medium-texture was an independent predictor of RFS. Intra-tumour 
heterogeneity has been attributed to various factors such as hypoxia, necrosis, angiogenesis 
and genetic variations.35 36 Both hypoxia and necrosis reflect increased numbers of dark 
tumour regions which tend to give a negative mean.16 MPP considers only pixels greater 
than zero and reduces the impact of dark areas on the mean histogram value. MPP has 
been correlated negatively with hypoxia in colorectal cancers exhibiting K-RAS mutations.37 
Lower than threshold MPP values in predicting an inferior outcome are consistent with the 
possibility of predominance of hypoxic areas in rectal cancer rather than angiogenesis in our 
study. The finding of lower kurtosis at medium texture predicting poorer DFS and RFS on 
post-treatment MRTA may suggest more focal radiation induced inactive fibrosis which has 
previously been associated with an inferior outcome in lung cancer.38 Post-treatment MR 
EMVI status was an independent predictor of OS on multivariate analysis. These results are 
similar to those of Chand et al.39 In this database patients with ymrEMVI-positivity had a 
significantly worse DFS at three years (42.7%) compared with ymrEMVI-negative tumours 
(79.8%). MRI CRM status at pre- and post CRT was noted to be significant on multivariate 
analysis for DFS, while mrTRG and ymrEMVI were also significant for DFS on univariate 
analysis. This is similar to previous datasets from Patel et al. 19 (where mrTRG was 
significant on multivariate analysis for OS and DFS) and Taylor et al. 40 (where involvement 
of CRM on baseline MRI independently predicted OS, DFS, and LR on multivariate 
analysis). Significant univariate histopathological parameters such as ypCRM, pCR and 
ypTRG did not predict survival independently on multivariate analysis. 
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Limitations of the study 
There is a lack of validated published histological correlations of tumour heterogeneity for 
different MR texture scales in rectal cancer. This is a first exploratory and hypothesis-
generating study with regard to MRTA in survival after treatment of rectal cancer. The data 
are, however, based on small numbers of patients from one centre. Using the same data to 
identify optimal cut-off values for each marker to divide the population into good and bad 
prognostic groups could lead to the overstatement of significant results. Acquisition 
parameters with MRI can introduce higher signal intense variability compared with 
computerised tomography (CT) or positron emission tomography (PET) which in theory 
could affect reproducibly of the results. 
The study suggests that high resolution pre- and post-treatment MRI-based assessment of 
CRM and EMVI status and MRTA are superior to Independent imaging markers for 
predicting survival in locally advanced rectal cancer than the standard TNM-based MR 
criteria. Treatment for this group could be tailored for example, with more intensive 
individualized neoadjuvant treatment before undergoing surgery and adjuvant 
chemotherapy. 
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Table 1  Baseline characteristics of the patients 
TEMS= transanal microsurgery 
TME=total mesorectal excision 
NA= not available 
TRG= tumour regression grade 
Male 
Female 
 
34 (61%) 
22 
Age (years median ± SD) 64±8.82 
Interval to surgery after completing long 
course chemo-radiotherapy (weeks median ± 
SD)  
13±3.42 
Operation  
Anterior resection 
Abdominoperineal resection 
Hartmann’s procedure 
TEMS 
inoperable at surgery 
No surgery (disease progression) 
 
33 (59%) 
16 (28%) 
2 (4%) 
1 (2%) 
3 (5%) 
1 (2%) 
TME Laparoscopic  
        Open  
47 (84%) (4 converted to open) 
4 (7%) 
Height of tumour from anal verge(cm) 
>5 
<5 
 
39 (70%) 
14 (25%) 
ypCRM involvement 6 (11%) 
yp T-stage 
T0 
T2 
T3 
T4 
 
14 (25%) 
14 (25%) 
20 (36%) 
4   (7%) 
yp N-stage 
N0 
N1 
N2 
 
36 (64%) 
14 (25%) 
2 (4%) 
Complete pathological response T0N0 12 (21%) 
R0 resection 
Yes 
No 
 
46 (82%) 
6 (11%) 
yp tumour regression grade( 0-4) ͣ  
0 
1 
2 
3 
4 
NA 
Not documented 
 
3   (5%) 
12 (21%) 
10 (18%) 
1   (2%) 
14 (25%) 
4   (7%) 
12 (21%) 
yp tumour regression grade 
Good responders (TRG 2-4)  
Bad responders (TRG 0-1) 
 
25 (47%) 
15 (27%) 
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Adjuvant Chemotherapy 
Yes 
No 
 
11 (20%) 
42 (75%) 
Major post-operative complication ᵇ 
Yes 
No 
 
17 (30%) 
35 (63%) 
Anastomotic leakage 
Yes 
No 
 
6 (18%) 
27  
Overall Recurrence 13 (23%) 
Local Recurrence 3 (5%) 
Distant  Recurrence 11 (19%) 
 
ͣ  Dworak 5-stage TRG (tumour regression grade) system23 
ᵇ Clavien classification of surgical complications34 
 
Table 2  Magnetic resonance imaging (MRI) pre and post chemorqdiotherapy  
TRG= tumour regression grade in locally advanced rectal cancer. 
 Pre-treatment MRI Post-treatment  MRI 
T-stage  
T0 
T1 
T2 
T3a 
T3b 
T3c 
T3d 
T4 
 
 
 
 
4 (7%) 
3 (5%) 
11 (20%) 
12 (21%) 
10 (18%) 
14 (25%) 
 
3 (5%) 
2 (4%) 
7 (13%) 
1 (2%) 
13 (23%) 
14 (25%) 
5 (9%) 
9 (16%) 
N-stage 
N0 
N1 
N2 
 
14 (25%) 
24 (43%) 
16 (29%) 
 
40 (71%) 
12 (21%) 
0 
Circumferential resection 
margin (CRM) threatened 
31 (55%) 24 (43%) 
Median tumour height from 
anal verge (cm) 
8.4 8.7 
Tumour regression grade 
(mrTRG) (grade 1-5)ͣ 
1 
2 
3 
4 
5 
  
 
6 (11%) 
17 (30%) 
13 (23%) 
16 (29%) 
2 (4%) 
Tumour regression (mrTRG) 
Good responders (1-3)  
Bad responders (4-5) 
  
36 (64%) 
18 (32%) 
Complete responder T0N0  6 (11%) 
Extramural vascular invasion   
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(EMVI) 
Yes 
No 
 
 
14 (25%) 
40 (71%) 
 
8 (14.2%) 
44 (79%) 
 
ͣ MRI TRG was based on similar principles to the pathological TRG originally described by 
Dworak (Appendix-3) 
 
 
Table 3  Magnetic resonance imaging (MRI) Textual analysis.Significant parameters 
predicting overall survival (OS), disease free survival (DFS) , and recurrence free 
survival (RFS) on univariate analysis 
MPP= mean of positive pixels 
EMVI= extramural vascular invasion 
Textural parameter Filter value Threshold value Number 
of 
patients 
above 
and 
below the 
threshold 
value 
Mean 
Survival
95% 
Confidence 
interval 
p value
Overall Survival: Significant pre-treatment texture parameters 
Mean 3 <-8.2 Poor 27 45.4 38.4-52.3 0.03 
Good 29 72.8 62.5-83.2 
MPP 2 <63.7 Poor 17 40.7 29.2-52.2 0.008 
Good 39 72.2 63.5-80.9 
3 <75.2 Poor 19 43.5 32.5-54.4 0.029 
Good 37 71.6 62.7-80.5 
4 <82.3 Poor 22 45.6 35.8-55.3 0.019 
Good 34 74.3 65.6-83 
Overall Survival: Significant post-treatment texture parameters 
Skewness 2 >0.3 Poor 36 38.9 27.3-50.6 .034 
Good 18 65.7 55.-76.3 
DFS: Significant pre-treatment texture parameters 
Mean 2 <-3.5 Poor 25 39.2 30.6-47.7 0.031 
Good 31 68.6 57.3-79.8 
3 <-8.2 Poor 27 38.2 30.1-46.3 0.007 
Good 29 71.3 60.0-82.5 
4 <-14.9 Poor 27 39.4 31.2-47.7 0.027 
Good 29 69.2 57.75-80.8 
6 <-37 Poor 28 40.2 32.11-48.3 0.043 
Good 28 68.6 56.81-80.4 
MPP 2 <64.4 Poor 18 37.1 25.38-48.9 0.022 
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Good 38 66.8 56.66-77. 
3 <75.2 Poor 19 38.7 27.2-50.3 0.045 
Good 37 66.3 55.9-76.7 
4 <84.7 Poor 24 40.3 30.2-50.4 0.022 
Good 32 69.7 59.1-80.3 
5 <93.5 Poor 28 42.2 32.7-51.6 0.047 
Good 28 69.6 58.4-80.8 
6 <102.4 Poor 28 42.2 32.7-51.6 0.047 
Good 28 69.6 58.4-80.8 
Skewness 2 <0.2 Poor 28 42.3 33.2-51.4 0.044 
Good 28 69.2 57.7-80.7 
DFS: Significant post-treatment texture parameters 
MPP 2 >69.5 Poor 37 43 34.9-51.1 0.032 
Good 17 74 61.1-86.8 
Skewness 2 >0.3 Poor 18 38.9 27.3-50.6 0.034 
Good 36 65.7 55-76.3 
Kurtosis 3 <-0.1 Poor 20 36.8 28-45.2 0.042 
Good 34 65.7 54.4-76.9 
4 <-0.4 Poor 18 34.7 25.9-43.5 0.009 
Good 36 67 56.3-77.7 
RFS: Significant pre-treatment texture parameters 
Mean 3 <-870000 Poor 26 43.4 35.1-51.7 0.0169 
Good 30 80.7 72.3-89.1 
4 <-14.9 Poor 27 44.1 36-52.1 0.026 
Good 29 80.4 71-89.1 
Standard Deviation 0 <39.7 Poor 21 47.3 35.9-58.7 0.032 
Good 35 77.6 68.8-86.5 
2 <137.5 Poor 38 64.1 52.9-75.4 0.034 
Good 18 64.5 58.7-70.3 
4 <151.4 Poor 28 50.5 39.7-61.3 0.018 
Good 28 80.7 72.2-89.1 
5 <164.8 Poor 32 61.5 48.8-74.2 0.017 
Good 24 63.2 57.5-69 
6 <162.2 Poor 31 50.8 40.7-61 0.011 
Good 25 82.7 74.9-90.5 
Entropy 0 <5.1 Poor 33 52.6 43.1-62.1 .034 
 Good 23 81.7 72.6-90.8 
4 <6.3 Poor 32 61.5 48.8-74.2 0.016 
 Good 24 63.2 57.5-69 
5 <6.3 Poor 32 61.5 48.8-74.2 0.016 
 Good 24 63.2 57.5-69 
6 <6.3 Poor 31 50.8 40.7-61 0.011 
 Good 25 82.7 74.9-90.5 
MPP 2 <63 Poor 16 42.8 29.4-56.2 0.011 
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Good 40 77.3 69-85.6 
5 <118 Poor 31 50.8 40.7-61 0.011 
Good 25 82.7 74.9-90.5 
6 <99 Poor 27 47.9 38.1-57.7 0.019 
Good 29 80.5 71.9-89.1 
Skewness 2 <0.4 Poor 38 50.8 42.9-58.8 0.037 
Good 18 84 75.4-92.6 
Kurtosis 4 <0.09 Poor 17 40.1 30.9-49.4 0.047 
Good 39 76.4 67.5-85.3 
RFS: Significant post-treatment texture parameters 
Standard deviation 5 <128.5 Poor 18 56.2 39.4-73 0.018 
Good 36 60.9 54.6-67.2 
6 <158.1 Poor 30 61.1 48.3-73.9 0.021 
Good 24 63.5 57.3-69.6 
Entropy 3 <6.1 Poor 28 61.6 48.3-74.9 0.042 
Good 26 61.8 55.1-68.5 
4 <6.1 Poor 26 57.9 44.1-71.7 0.005 
Good 28 64.1 58.6-69.5 
5 <6.1 Poor 25 56.7 42.6-70.8 0.003 
Good 29 64.2 59.0-69.5 
6 <6.1 Poor 24 55.4 40.9-69.8 .002 
Good 30 64.4 59.3-69.4 
Kurtosis 0 >0.7 Poor 17 45.5 32.8-58.2 .034 
Good 37 76.1 67.1-85.2 
 
 
Table 4  Clinical, MRI and histopathological parameters significantly predicting overall 
survival (OS), disease free survival (DFS) , and recurrence free survival (RFS) on 
univariate analysis  
Parameters 
  
n= 
Mean OS
(95% CI) 
p-
valu
e 
Mean DFS 
(95% C1) 
P-
valu
e 
Mean 
RFS(95% 
CI) 
P-
valu
e 
Clinical parameters 
Age 
 
<65 years  29 50.7 (42.8-58.6) .271 
46.3(37-
55.5) .444 
51.7(42.5-
61) .150 
≥65 years 27 69.3 (58-80.6)  
63.5(51-
75.9)  
77.1(66.8-
87.3)  
Sex 
Female 22 52.4 (44.1-60.7) .633 
47.1 (37.2-
57) .711 
52 (42.1-
61.9) .360 
Male 34 65.7 (56.5-77.5)  
61.7(50.1-
73.3)  
74.2(64-
84.5)  
Adjuvant 
chemothera
py 
Positive 11 55.9(42.7-69.1) .628 
52.4(36.4-
68.3) .948 
52.4(36.4-
68.3) .321 
Negative 42 69.1(60.3-77.9)  
62.7(52.6-
72.8)  
72.5(63.2-
81.8)  
Major Positive 17 39.9(30.6- .002 35.7(25.7- .007 42.7(31.9- .132 
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complication 49.2) 45.8) 53.5) 
Negative 35 77.4(70-84.7)  
71.3(61.5-
81.1)  
74.2(64.7-
83.8)  
Anastomotic 
leak 
Positive 6 49.9(34.9-64.8) .174 
47.6(28.8-
66.3) .280 
52.7(38.4-
66.9) .795 
Negative 27 74.8(65-84.6)  
70.1(58.4-
81.9)  
72.4(61-
83.7)  
Pre-treatment MRI parameters 
mrT Stage 
 
MrT1-T3a 7 62.3(53.1-71.5) .256 
54.1(38.4-
69.7) .493 
54.1(38.4-
69.7) .989 
mrT3b-T4 47 65.3(56.5-74.2)  
60.4(50.6-
70.3)  
70.6(61.4-
79.8)  
mrN stage 
 
mrN0 14 54.3(43.3-65.4) .799 
47.9(35.5-
60.3) .714 
55.6(43.8-
67.4) .895 
mrN1&2 40 66.6(57.3-75.9)  
62.1(51.5-
72.7)  
69.9(59.9-
79.9)  
mrEMVI 
status Positive 14 
46.1(33.6-
58.5) .017 
42.8(28.9-
56.7) .097 
51.5(36.8-
66.2) .221 
Negative 40 72.5(63.9-81.2)  
65.8(55.6-
76)  
73.4(64.1-
82.8)  
Height 
<5cm 14 46.8(37.9-55.6) .315 
41.5(30.6-
52.5) .226 
50.3(39.5-
61.1) .973 
≥5cm 39 66.9(58.7-75.1)  
65.1(54.7-
75.6)  
71.3(61.5-
81.1)  
mrCRM 
status 
 
Clear 23 77.5(67.6-87.4) .036 
76.9(66.5-
87.3) .006 
82.4(74.2-
90.5) .016 
 Threatened  31 
 52.1(43.8-
60.5)   
44(34.4-
53.65)  
51.41(41.3-
60)  
Post-treatment MRI parameters 
ymrT stage 
 
ymrT1-T3a 13 64.3(58.4-70.1) .056 
57.3(47.3-
67.4) .194 
60.2(51-
69.4) .306 
ymrT3b-T4 41 62.9(53.4-72.4)  
58.1(47.4-
68.8)  
67.8(57.5-
78.2)  
ymrN stage 
 
ymrN0 41 70.7(61.7-79.8) .171 
65(54.9-
75.1) .278 
75.4(66.5-
84.2) .024 
ymrN1&2 12 49.9(39-60.8)  
42.8(28.5-
57.2)  
42.8(28.5-
57.2)  
ymrEMVI 
status Positive 8 
38.3(23.8-
52.7) .002 
33.2(18.2-
48.2) .017 
46(27.6-
64.4) .236 
Negative 44 72.4(64.1-80.7)  
66.1(56.3-
75.9)  
73.2(64.2-
82.1)  
Height 
<5cm 13 48.3(39.2-57.4) .661 
42.7(31-
54.3) .445 
49.5(38-
61) .895 
≥5cm 38 66.9(57.3-76.6)  
62.9(52.2-
73.7)  
70.8(60.8-
80.9)  
ymrCRM 
status 
 
Clear 29 76(67-85) .027 71.4(60.2-82.5) .019 
75.7(65.5-
86) .141 
Threatened 24 49.8(40-59.5)  
43.4(32.8-
54)  
52.7(41.5-
63.9)  
mrTRG 
status 
 
mrTRG1-
3(Good 
responders) 
36 63.9(58-69.9) .002 57.8(49.8-65.8) .022 61.5(54-69) .205 
mrTRG 4-5 
(Bad 18 
50.3(35.8-
64.7)  
47(31.5-
62.6)  
62.2(45.3-
79)  
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Table 5  Parameters significantly predicting overall survival (OS), disease free survival 
(DFS) ,and recurrence free survival (RFS) on univariate analysis 
Pre-treatment multivariate analysis 
Survival endpoints parameters p-value Hazard ratio 95% confidence interval 
OS Mean (SSF-3) 0.007 5.7 1.6 – 20.2 
MPP(SSF-2) <0.001 6.9 2.4 – 19.5 
mrEMVI status 0.041 2.9 1 – 8.37 
DFS Mean(SSF-3) 0.003 4.5 1.5 – 12.9 
MPP(SSF-2) 0.008 3.3 1.3 – 8.3 
mrCRM status 0.046 3.1 1 – 9.4 
RFS MPP(SSF-2) 0.001 8.9 2.3 – 33.1 
Kurtosis(SSF-4) 0.002 7.7 2 - 29 
Post-treatment multivariate analysis 
OS ymrEMVI status 0.01 4.2 1.4-12.6 
DFS Kurtosis(SSF-4) 0.007 3.9 1.4– 10.9 
ymrCRM status 0.02 3.3 1.2 – 9.3 
RFS Entropy(SSF-6) 0.005 8.6 1.8 – 39.8 
Kurtosis(SSF-0) 0.01 4.2 1.4- 13 
 
responders) 
mrRECIST 
tumour 
response 
 
Partial 
response 36 
69.4(59.9-
78.8) .319 
62.1(51.2-
73) .625 
71.9(61.8-
82.1) .417 
Stable 
disease 16 
51.3(38.6-
63.9)  
47.9(34-
61.9)  
53.9(40.5-
67.4)  
Histopathological parameters 
ypT stage 
 
ypT0-T2 13 64.3(58.4-70.1) .056 
57.3(47.3-
67.4) .194 
60.2(51-
69.4) .306 
ypT3-T4 41 62.9(53.4-72.4)  
58.1(47.4-
68.8)  
67.8(57.5-
78.2)  
ypN stage 
 
ypN0 36 73(64.2-81.8) .126 
67.6(57.3-
78) .142 
74.2(64.7-
83.7) .138 
ypN1-2 16 48.9(38.3-59.4)  
42.8(30.6-
55)  
47.1(34.6-
59.5)  
ypCRM 
involvemen
t 
  
Clear 46 72.3(64.3-80.2) .007 
66.1(56.7-
75.5) .058 
73.9(65.3-
82.5) .009 
Threatened 6 35.1(23.1-47.1)  
30.6(16.2-
45)  
30.6(16.2-
45)  
pCR 
(ypT0N0M0
) 
 
Positive 12 82.4(70.9-93.9) .073 
82.4(70.9-
93.9) .035 
All cases 
censored .034 
Negative 40 56.2(49.4-63)  
49.4(41.1-
57.6)    
pTRG 
Good 
responder 
(pTRG 2-4) 
25 72.8(61.7-83.9) .934 
71.6(59.7-
83.5) .949 
82.2(73.7-
90.7) .159 
Bad 
responder(p
0-1) 
15 61.2(51.2-71.1)  
58.3(46.2-
70.4)  
58.3(46.2-
70.4)  
pTRG 
Complete 
response 
(pTRG 4) 
14 77.8(63.9-91.6) .354 
77.8(63.9-
91.6) .301 
All cases 
censored .072 
Incomplete 
or no 
response 
26 60.3(52.7-67.9)  
57.4(48-
66.7)  
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Figure 1a- Textural analysis of rectal cancer at medium-texture scale for baseline magnetic 
resonance imaging (MRI) 
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Figure 1b- Textural analysis (MRTA) of rectal cancer at medium-texture scale for interim 
magnetic resonance imaging (MRI) 
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Figure 2- Kaplan-Meier curves show a significant difference in overall survival for (a) pre-treatment mean positive pixel 
(MPP) at fine texture (b) pre-treatment mean at medium texture (c) pre-treatment extramural venous invasion 
(mrEMVI) and (d) post-treatment extramural venous invasion (ymrEMVI) with log-rank p values of 0.008, 0.03, 0.017 and 
0.002 respectively 
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Figure 3-Kaplan-Meier curves show a significance difference in disease free survival for (a) pre-treatment mean positive 
pixel (MPP) at fine texture (b) pre-treatment mean at medium texture (c) pre-treatment circumferential resection 
margin involvement (mrCRM) (d) post-treatment kurtosis at medium texture (e) post-treatment circumferential 
resection margin involvement (ymrCRM) with log-rank p values of 0.022, 0.007, 0.006, 0.009 and 0.019 respectively. 
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Figure 4-Kaplan-Meier curves show a significance difference in recurrence free survival for (a) pre-treatment mean 
positive pixel (MPP) at fine texture (b) pre-treatment kurtosis at medium texture (c) port-treatment entropy at coarse 
texture and (d) post-treatment kurtosis without filtration with log-rank p values of 0.011, 0.047, 0.002 and 0.034 
respectively 
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